Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free

Recent Articles

Happy News

This Record Holding Martial Arts Star Just Popped 35 Balloons With Her Heel

April 30, 2026

Meet Fatima Naseem. She is 12 years old, holds a black belt in martial arts, and on February 1 she strapped on a pair of high heels and kicked 35 balloons above her head in under 60 seconds, shattering the previous record by 13 balloons. She earned herself an official

Read More
Happy News

The FDA Reversed A 20-Year Warning On Hormone Therapy And Now The Demand Has Changed Everything

April 30, 2026

For decades, millions of women going through menopause were told to avoid hormone replacement therapy based on a 2002 study that linked estrogen use to elevated risks of heart attack and stroke, and prescriptions plummeted. Last year, the FDA reversed course, removing the longstanding black box warning from estrogen products

Read More
Happy News

Five Middle Schoolers Just Took Control Of A Bus After Their Driver Blacked

April 30, 2026

A school bus carrying about 40 students had just left Hancock Middle School in Hancock County, Mississippi on April 22nd when driver Leah Taylor, 46, suffered a severe asthma attack and blacked out at the wheel on a four-lane highway, leaving the moving vehicle with nobody in control. What happened

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.